# Progress Note 06 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sonny Liston (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX007-SYN
- Date: 2026-09-22
- Fictional facility: St. Posthumous Health Center
- Fictional author: Malcolm Achebe-Whitford, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month review of blood pressure and drinking. **S**

## History of present illness

Sonny Liston returns two weeks after a cold, for which he stopped an over-the-counter decongestant; his home readings came back down within two days and have averaged 124/78 mmHg over the past week. He takes amlodipine 10 mg and valsartan 160 mg and naltrexone 50 mg each morning. Mild ankle swelling after long runs in the heat goes by morning. He drinks three or four drinks on one or two evenings a week and has not had more than four on any day since starting naltrexone; the urge to keep going is much weaker. He saw the dentist about his molar. He wants to start sparring hard again. No thoughts of suicide. **S**

| Element | Detail |
|---|---|
| Home readings | Average 124/78 mmHg |
| Liver tests | AST 31, ALT 30, GGT 54 U/L |
| AUDIT-C | 4 |
| Vaccine today | Second hepatitis B dose |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Mild ankle swelling after long runs, gone by morning; no chest pain or palpitations |
| Ears, nose, mouth, and throat | Negative | Cold symptoms gone |
| Gastrointestinal | Negative | No nausea on naltrexone |
| Psychiatric | Negative | Mood good; no thoughts of suicide |

4 systems reviewed. **S**

## Current medications

- Amlodipine 10 mg and valsartan 160 mg combined oral tablet, one tablet each morning **S**
- Naltrexone 50 mg oral tablet, one tablet each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/78 mmHg; pulse 56 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 97.2 kg; BMI 28.4 kg/m². All vital signs are synthetic.

AST: 31 U/L; ALT: 30 U/L; GGT: 54 U/L; AUDIT-C: 4. All results are synthetic.

## Change since baseline

- AST: 46 U/L (high) at baseline, 31 U/L at this visit **S**
- ALT: 38 U/L at baseline, 30 U/L at this visit **S**
- GGT: 88 U/L (high) at baseline, 54 U/L at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 126/78 mmHg (average of two); pulse 56; weight 97.2 kg |
| Cardiovascular | Regular rhythm; trace ankle edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypertension, stage 2** (I10). At goal in the clinic and at home; trace ankle edema from amlodipine is tolerable. Controlled blood pressure meets the cardiologist's condition for returning to competition. **S**
   - Continue amlodipine 10 mg and valsartan 160 mg.
   - Letter to the commission physician for the pre-bout examination, with his readings.
   - No decongestants or ibuprofen-type pain pills; picture card reviewed.
2. **Alcohol use disorder, moderate** (F10.20). Within his goal on naltrexone; liver tests improving. **S**
   - Continue naltrexone.
   - Full AUDIT and GGT at the next visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, large cuff, average of two readings), weight and BMI, heart sounds | Every visit | Completed today | 126/78 mmHg; weight 97.2 kg |
| Examination | Out-of-office blood pressure (ambulatory or home monitoring) | At diagnosis and after each treatment change | Completed today | Home average 124/78 mmHg by voice message |
| Laboratory | Potassium, creatinine and eGFR | Baseline; two to four weeks after starting an ARB; then every six months on an ARB | Up to date | Potassium 4.4 and creatinine 1.1 two months ago; next in about four months |
| Examination | Fundoscopic examination | Yearly | Up to date | Normal at the preventive visit |
| Survey | Cardiovascular risk estimate | Yearly | Up to date | Low at the preventive visit; statin not indicated |
| Medication safety | Antihypertensive tolerance (ankle edema, dizziness) and adherence by teach-back | Each follow-up and each dose change | Completed today | Trace ankle edema after long runs; no dizziness; teach-back correct |
| Referral | Fitness to compete (AHA/ACC athlete statement) | At diagnosis and before returning to competition | Completed today | Controlled; letter to the commission physician for clearance |
| Survey | Drinking (AUDIT-C, drinks per week, drinking days) | Every follow-up during treatment; full AUDIT at about four months | Completed today | AUDIT-C 4; about 7 drinks a week, no day above 4 |
| Laboratory | Liver tests (AST, ALT, GGT) | Baseline; about two months after starting naltrexone or cutting down; then as indicated | Completed today | AST 31, ALT 30, GGT 54 U/L, two months after starting naltrexone |
| Medication safety | Naltrexone: nausea, liver tests, and opioid-blockade wallet card | Each follow-up after starting | Completed today | No nausea; liver tests improving; carries the wallet card |
| Survey | Suicide-risk review (structured questions) and safety plan | Every visit | Completed today | No thoughts of suicide |
| Self-management | Health literacy: teach-back, picture card, read-aloud consent, voice reminders | Every visit | Completed today | Teach-back of the medicines to avoid correct; the pharmacist now reads labels to him |

## Goal progress

- Confirm or rule out hypertension with out-of-office readings before any medicine. Outcome by 2026-06-23: Ambulatory monitoring confirmed stage 2 hypertension (daytime 146/94 mmHg). **S**
- Blood pressure under 130/80 mmHg in the clinic and at home by four months. In progress; target 2026-10-20. **S**
- Drink within the goal he set: no more than 14 drinks a week and no more than 4 on any day, and none in the two weeks before a fight. In progress; target 2026-10-20. **S**
- Explain his medicines and blood pressure plan back in his own words. Outcome by 2026-07-21: Teach-back correct at four weeks with the picture card. **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- CMID: Clinical Monitoring Intelligence Database, hypertension and depression monographs (2026), Aether Forge
- Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (Black HR, et al.) (2015), American Heart Association and American College of Cardiology (Circulation 2015)
- The Healthcare Professional's Core Resource on Alcohol (2026), National Institute on Alcohol Abuse and Alcoholism
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition (2024), Agency for Healthcare Research and Quality
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Four-month review in four weeks with the full AUDIT, GGT and PHQ-9, and the influenza vaccine. Call 988 or the clinic at any time if thoughts of suicide arise. **S**
- Next scheduled visit 2026-10-20: four-month review: blood pressure at goal, AUDIT, and the plan ahead. **S**
